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Slow-wave sleep-promoting "factor S" was described in the past fifteen years 
by Fenci et al.  (1) and  Pappenheimer and colleagues (2,  3) as a  constituent of 
cerebrospinal fluid (CSF) j derived from sleep-deprived animals.  More recently, 
factor S  obtained  from  urine  and  brain  was  provisionally identified  as  a  low 
molecular  mass  muramyl  peptide  (-1,000  D)  (4).  In  rabbits,  10  pmol  of this 
material  was sufficient to induce excess slow-wave sleep (SWS) for six or more 
hours (4). In cats, similar increases in SWS (5) were induced by amounts of factor 
S  calculated  to be  ~100  pmol.  The  similarity  of the  chemical composition  of 
factor S to subunits of some bacterial peptidoglycans led to investigations of the 
effects on sleep of synthetic muramyl peptides such as N-acetyl-muramyI-L-alanyl- 
D-isoglutamine (NAc-mur-L-ala-o-isogln) (MDP).  MDP or its L-lysine derivative 
were  found  to  induce excess SWS  in  rabbits  (6),  cats  (6),  and  monkeys (7)  at 
molar  levels  10-fold  that  of factor  S.  The  dose  required  in  the  rabbit  was 
dependent on the route of administration, with the highest dose required in oral 
administration, followed by intraperitoneal, intravenous, and intraventricular. 
MDP is an immunostimulant that was first described as the minimal adjuvant- 
active  structure  that  can  substitute  for  mycobacteria  in  Freund's  complete 
adjuvant (8).  It is also a  pyrogen (9,  10) and many of its derivatives have been 
examined for these two activities (1 1).  Furthermore, it may act as a  bactericidal 
agent  in  at  least  two  ways.  It  may act  on  macrophages  so  that  they  produce 
augmented amounts of oxygen radicals (12,  13) and it also enhances production 
of interleukin  1 by macrophages (14).  More recently supernates from activated 
macrophages have been shown to induce excess SWS. 2 
In  the present paper,  the list of MDP  derivatives that induce SWS has been 
extended. Further, some analogs that do possess immunostimulatory and pyro- 
This work was supported by grant ONR-N00014-82-K-0393 from the Office of Naval Research and 
grants RR-5366 and AI03260 from the National Institutes of Health. 
J Abbreviations used in  this paper:  CSF, cerebrospinal fluid; dap, diaminopimelic acid; E~, mean 
rectified slow-wave  voltage during waking periods; El, mean rectified slow-wave voltage during slow- 
wave sleep periods; EEG, electroencephalograph; MDP, NAc-Mur-L-ala-D-isogln; SWS, slow-wave 
sleep. 
2 Krueger, J. M., J. Walter, C. A. Dinarello, S. M. Wolff, and L. Chedid. Sleep-promoting effects 
of endogenous pyrogen (interleukin 1). Manuscript submitted for publication. 
68  j. Exe. MED. © The Rockefeller University Press - 0022-1007/84/01/0068/09 $1.00 
Volume 159  January 1984  68-76 KRUEGER  ET  AL.  69 
genic activities  have been  shown  to  lack  somnogenic activity.  We also present 
some  tentative  conclusions  as  to  the  structural  requirements  for  somnogenic 
activity.  Of these  the  most notable  is that  amidation  of the  free 3,-carboxyl of 
MDP and several of its analogs results in a  loss of somnogenic activity. 
Materials 
The  MDP  used  was from Institut  Pasteur  Productions,  Paris,  France.  Derivatives of 
MDP were obtained from the following sources (compound numbers are those shown in 
Table I):  Numbers  2-11  (inclusive) and  15  were obtained from Institut Choay,  Paris; 
numbers  13 and  14 were gifts from Dr. T. Y. Sben, Merck and Co.,  Inc., Rahway, NJ; 
number 12 was isolated from Bacillus cereus grown in the presence of vancomycin and was 
a gift from Dr. J. F.  Petit,  lnstitut de Biochimie, Universite de Paris-Sud, Orsay, France 
(15);  number  16  was  prepared  as  previously described  (6).  All  other  chemicals  were 
reagent grade. Needles, syringes, glassware, and solutions were sterile and pyrogen free. 
Methods 
Male  New  Zealand  rabbits  (3-5  kg)  were  provided  with  chronically  implanted 
electroencephalographic  (EEG) electrodes and  cerebral  ventricular guide  tubes  under 
Nembutal anesthesia  (15-30  mg/kg),  as  previously described  (16).  At  least  1 wk  was 
allowed  for recovery from the  operation.  Before each  recording  period animals were 
brought to the experimental cages for an overnight acclimation period.  Each substance 
was dissolved in artificial CSF (155 mM NaC1, 3 mM KC1, 1.15 mM CaCI,~, and 0.96 mM 
MgCI2) (16);  0.3 ml of each solution was infused into a lateral cerebral ventricle at a rate 
of 7 ul/min. After the infusion, the EEG, its rectified slow-wave component (0.5-4 Hz), 
and bodily movements were recorded for the next 6 h as previously described (16).  The 
0.5-4  Hz EEG component was also electronically integrated and integrals were printed 
on tape every minute. Rectal temperatures were taken using a calibrated thermistor probe 
(Yellow Springs Instrument Co.,  Yellow Springs,  OH) inserted  10  cm into the rectum 
immediately after the infusion and 3 and 6 h later. Both experimental and housing rooms 
were on a  12-h light-dark cycle (0600-1800  h, light).  Infusions took place between 0800 
and 1000 h. 
Polygraph recordings were  analyzed visually to determine  duration  of SWS;  values 
obtained by this method are shown in Table I and Fig.  1. Printed integrals were used to 
calculate the  mean,  rectified  slow-wave voltages associated with  SWS  periods (Es) and 
waking periods  (E,);  such  values are applied  in  Fig.  1 and  in  the  text.  Details of the 
infusion, recording, and analysis methods have been given elsewhere (3,  16). 
Results 
Dose-Response Relationship for MDP.  The effects of five different doses of MDP 
are shown in Fig.  1 and Table I. Infusion of 10 pmol of MDP was insufficient to 
induce excess SWS.  Doses of 50 pmoi or greater induced significant increases in 
duration of SWS. The time course of sleep responses observed after doses of 50 
and  100 pmol was similar to that previously reported (6).  During the first hour 
after infusion,  SWS  values were similar to control  values.  Excess SWS  became 
manifest  during  the  second  hour  postinfusion  and  continued  throughout  the 
routine  6-h assay period.  When  doses were increased to  1 and  10 nmol, excess 
SWS  was  evident  during  the  1st  h  postinfusion.  At  all  doses,  SWS  appeared 
normal in the sense that it remained episodic; animals could be aroused and they 
awoke spontaneously from time to time to eat, drink, and groom. However, after 
infusion  of 10  nmol of MDP,  other  autonomic responses were observed;  these 
included  excess nasal  and  lacrimal  secretions.  Similar responses were observed t~ 
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FIGURE  1.  Effects of various doses of MOP on rectal temperatures, EEG slow-wave ampli- 
tude, and duration of SWS. (  ) Effects of MDP after intraventricular infusion of MDP in 
0.3 ml of artificial CSF; (---)  control values from same rabbits. (A) Rectal temperatures were 
taken  3  h  after  the  end  of the  infusion.  At  this time  febrile responses were  greatest.  (B) 
Amplitude of EEG slow waves; slow-wave (0.5-4 Hz) voltages during periods of SWS (F~) are 
shown. Voltages during waking periods (Ea) (not shown) were unaffected by MDP. (C) Duration 
of SWS; ordinate values are the percent of time occupied by SWS during a routine 6-h assay 
period after the infusion. The number above each point is the number of animals tested at 
each dose; the same animals were used to determine control values. In A, B, and C, values 
shown are mean ___ SEM; (*) denotes significant increase above corresponding control value; 
P  <  0.05  (paired  t  tests).  After  10  pmol  of  MDP,  experimental  values  were  similar  to 
corresponding control values. When the dose was increased to 50 pmol, the increases in rectal 
temperatures (A) and slow-wave amplitudes (B) were not significant but significant increases in 
duration of SWS (C) were observed. Larger doses induced significant increases in all three 
response parameters. 
70 KRUEGER  ET  AL.  71 
TABLE  I 
Biological Effects of Cerebral Intmve~triculttr Administration  of MDP a~d Related Compounds. 
Percent SWS 6 h 
postinfusion  Effect 
Compound  Dose  n* 
Somno-  Pyro-  Immuno- 
Control  Expt.  genic  genic*  stimulatory  § 
H~ttol 
Group I 
1.  MDP  0.01  4  374-2  394-4  -  -  +(8,21) 
0.05  4  37 -4-2  49 4- 31  +  + 
0.1  6  40 4- 2  62 _  71  +  + 
1.0  3  40 4- 2  76 4- 71  +  + 
10.0  4  37 4-  1  65 4- 61  +  + 
2.  NAc-Mur-L-ala-D-glu  0.2  4  38 4-  1  43 4- 3  --  --  +  (11, 21) 
2.0  4  36 4- 3  51  4- 31  +  + 
3.  NAc-Mur-L-ala-D-gln  0.2  2  28-44  32-32  -  -  +  (11) 
2.0  4  46 4-3  45-  1  -  + 
4.  NAc-Mur-L-ala-D-gl.u-  2.0  3  42 +  3  43 4-  1  -  --  +  (21, 25) 
(NH2)-NH2 
5.  NAc-Mur-L-ala-~glu-  2.0  4  43 4- 4  66 4- 41  +  +  +  (21) 
(OMe)-OMe 
6.  NAc-Mur-L-ala-D-glu-a-  0.2  2  38-40  47-61  +  +  +  (22) 
OMe  2.0  4  42 +  4  72 4- 41  +  + 
7.  NAc-Mur-L-ala-D-isogln-  2.0  6  39 4- 3  56 4- 71  +  +  +  (21) 
3,-OMe 
8.  NAc-Mur-L-ala-D-gln-a-  0.5  2  34-42  31-45  --  --  +  (23) 
OMe  s 
9.  NAc-Mur-L-ala-D-gln-n-  0.25  2  37-42  41-47  --  --  +  (11, 22) 
Bu ester 
Group II 
10.  NAc-Mur-L-ala-o-isogln-  0.13  5  35 _  2  60 _  31  +  +  +  (23) 
L-lys 
11.  NAc-Mur-L-ala-D-isogln-  0.15  2  36-44  68-68  +  +  ND 
L-tyr-OMe 
12.  NAc-Mur-L-ala-'r-D-glu-  0.02  3  41  +  2  46 +  3  -  -  +  (15) 
meso-dap-D-ala-D-ala  0.2  3  41  +  2  65 4- 51  +  + 
Group Ill 
13.  3-O-(D-2-propionyI-L-  0.2  2  33--44  35--43  --  --  ND 
ala-r)-isogln)-D-glucose  2.0  2  42-43  40-45  --  -- 
14.  NAc-glucosaminyl  (1-4)  0.2  4  45 +  3  60 +  51  +  +  +  (24) 
/3-MDP 
15.  NAc-Mur(N-Me)-L-ala-D-  0.2  2  37-42  32-47  --  --  +  (11) 
isogln 
16.  Periodate-cleaved  NAc-  0.2  2  40-44  38-42  -  ND  ND 
Mur-L-ala-D-isogln ~ 
* (+) >0.5 °C change; (-) no change. ND, not determined. 
*  If it =  2, range is given instead of SEM. 
§ This term includes situations in which antiinfectious activity rather than true immunoadjuvanticity 
was measured. Relevant references appear in parentheses. 
!  Significantly different from control (P <  0.05). 
Four rabbits were given  this derivative  intravenously (0.16-0.33  mg/kg); none exhibited excess 
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after intravenous injection of relatively large amounts (75-100 #g) of MDP (6). 
Dose-dependent increases in body temperature and amplitudes of EEG slow 
waves during SWS (E~) also occurred. These increases were significant after the 
infusion of 0.1-10 nmol of MDP. Slow-wave voltages during periods of wakeful- 
ness (E,) were not affected by any of the doses used. Previously it was reported 
that sleep-promoting factor S (3),  MDP (6), and interleukin  1,2 as well as sleep 
deprivation (3) cause similar increases in slow-wave amplitudes during SWS and 
that these increases were independent of the increases in body temperature.  2 
Comparison of Various Analogs of  MDP.  The effects of intraventricular infusion 
of MDP and several of its analogs on the duration of SWS are shown in Table I. 
Pyrogenic activities and  information  from  the  literature  regarding  immuno- 
stimulatory activities of these analogs are also summarized in Table I. In assessing 
the effectiveness of the various compounds, the following general criterion was 
used:  Compounds were considered active if a  dose of 2  nmol or less  induced 
significant increases in  SWS.  For  completeness, five compounds reported on 
earlier (Nos. 8, 9,  10,  15, and 16) are included, although data on these do not 
completely fit the criterion mentioned. 
The first set of substances discussed (Nos.  1-9) (group I) is concerned with 
derivatives in which various changes in the D-isogln  moiety of MDP are made. 
Replacement of isogln by glu (No.  2) results in reduced somnogenic potency; 
when isogln was replaced by gln (No. 3), the substance was not somnogenic at 2 
nmol infused. However, at this dose, No.  3 did induce significant increases in 
rectal  temperatures.  The  diamide  analog  of MDP  (No.  4)  failed  to  induce 
increases in either SWS or body temperature when 2 nmol were tested. On the 
other hand,  the dimethyl ester analog (No.  5) induced significant increases in 
SWS and rectal temperatures. Similarly, the glu-a-methyl ester analog (No.  6) 
induced significant  increases in  SWS  and  temperature,  and  the 3,-methyl, ~- 
amide analog (No. 7) was also an effective sleep promoter. However, as previously 
reported (6),  the a-methyl ester,  7-amide (No.  8)  and  the a-n-butyl ester,  ~- 
amide  (No.  9)  were  inactive,  as  might  be  expected  from  observations  with 
substance No. 3 above. These data suggest that conversion of the free 3,-carboxyl 
of the  glu  moiety of MDP  to  an  unsubstituted  amide  results  in  the  loss  of 
somnogenic activity. In addition, derivatives with an unsubstituted amide on the 
a-carboxyl are  more potent somnogenic agents  than  those with either a  free 
carboxyl or an a-methyl ester. 
Results obtained using derivatives in which the free carboxyl of the glu moiety 
of MDP  was  linked  to  a  substituted  amide (peptide  link)  (group  II)  were in 
marked contrast to those having an unsubstituted amide in  this position.  The 
coupling of either L-lys (No.  10) or L-tyr methyl ester (No.  11) to MDP resulted 
in active compounds. Moreover, the presence of a tripeptide (meso-dap-o-ala-D- 
ala) (dap, diaminopimelic acid) at the same position actually increased potency 
(compare Nos.  12 and 2). 
We also tested several substances with modifications of the muramyl moiety of 
MDP (group III). If D-glucose is substituted for the N-acetyl-glucosamine moiety 
of MDP (No.  13), sleep-promoting and pyrogenic activities were lost. However, 
sleep-promoting activity was retained in the disaccharide dipeptide in which N- 
acetyl-glucosamine is in glycosidic linkage to carbon No. 4 of muramic acid (No. KRUEGER  ET  AL.  73 
14). Previously we reported that the N-methyI-L-ala derivative of MDP (No.  15) 
as well as periodate-cleaved  MDP (No.  16) were inactive and these results are 
reproduced here. 
The sleep responses elicited in rabbits by somnogenic analogs of MDP were 
similar to those elicited by MDP. Sleep remained episodic and appeared normal 
despite simultaneous febrile responses. In addition, each somnogenic analog also 
induced increases in EEG slow-wave amplitudes during SWS (Es). Those analogs 
that  failed  to  induce  increases  in  SWS  also  failed  to  affect  EEG  slow-wave 
amplitudes. None of the inactive analogs appeared to decrease normal sleep at 
the levels tested. 
Discussion 
Sleep  deprivation,  which  results  in  the  accumulation  of endogenous  sleep 
promoters (1),  is  followed by  excess SWS,  which in  rabbits  (3)  and  rats  (17) 
remains episodic, alternating with bouts of rapid eye movement (REM) sleep and 
wakefulness. In rats, the amount of excess SWS observed after sleep deprivation 
is dependent upon the time of day. During daylight hours, there is little increase 
in sleep above normal daytime values (17,  18), but large increases are observed 
during dark hours (17). Normally, rats sleep 70-80% of the time during daylight 
hours,  during which time levels of endogenous sleep promoters are  probably 
high, whereas during dark hours rats are normally active.  Interestingly, intra- 
peritoneal injection of MDP into rats at the beginning of daylight hours does not 
induce an increase in the duration of SWS (19), whereas administration of M DP 
to rats at the onset of dark hours results in excess sleep (20). These observations 
suggest that MDP may elicit its effects on sleep through the same mechanisms as 
do endogenous substances. It is also noted that in rabbits, the duration of SWS 
after 24 h of sleep deprivation (3) was similar to the values reported here (Fig. 
1) after high doses of MDP. 
Many analogs of MDP have been examined for their immunostimulatory and 
pyrogenic properties (11); some of these were found to be immunostimulatory 
but not pyrogenic (11).  However, all those that were pyrogens were also found 
to be immunostimulants. Similarly, in the present paper we showed that some 
immunostimulants (Nos. 3, 8, 9,  15) and one pyrogenic derivative (No. 3) were 
not somnogenic. However, each agent that was somnogenic was also an immu- 
nostimulant and a pyrogen. It was previously shown (6) that pyrogenic actions of 
MDP could be suppressed with antipyretics without affecting sleep responses. 
Thus, through the use of various derivatives or through pharmacologic manip- 
ulation, these major actions of muramyl peptides can be separated, in part, from 
each other. 
In  the  present  study,  we  have  amplified  our  understanding  of  structural 
requirements for somnogenic activity by muramyl peptides.  Previously we re- 
ported (6)  that the adjuvant-inactive stereoisomers of MDP  (NAc-mur-L-ala-L- 
isogln and NAc-mur-D-ala-D-isogln) were inactive and that periodate oxidation 
of the muramyl moiety of MDP also led to the loss of somnogenic activity. With 
regard to this latter observation, we have now shown that replacement of the N- 
acetyl-glucosamine moiety of MDP by glucose also led to inactivity. Addition of 
N-acetyl-glucosamine in/3  1-4 linkage to muramic acid in MDP (i.e., the disac- 74  MURAMYL PEPTIDES AND SOMNOGEN1C ACTIVITY 
charide monomer form found in  bacterial  cell wall  peptidoglycans) does not 
block  sleep-promoting activity.  We  also  present  evidence indicating that  the 
presence  of an  unsubstituted  amide  on  the  free  carboxyl  of MDP  leads  to 
inactivity. However, if this position is in peptide linkage, somnogenic activity was 
retained or even enhanced. Our findings lead to the interesting hypothesis that 
perhaps specific mammalian amide-synthesizing or -hydrolyzing enzymes exist in 
the body that have the capacity to control the somnogenic activity of muramyl 
peptides. 
Currently  it  is  thought  that  the  immunological  and  pyrogenic  effects  of 
muramyl peptides are mediated through the monokine, interleukin  1. Further- 
more, we have recently shown that cerebral intraventricular administration of 
interleukin  1  can  also  induce dose-dependent increases in  SWS. 2 Thus,  it  is 
possible that the functional role(s) of exogenous muramyl peptides in mammalian 
physiology could be analogous to those of vitamins and/or essential amino acids 
in  that  they may be  incorporated into  larger entities in  order to  exert their 
normal physiological action(s). 
Summary 
Sleep-promoting activities  of muramyl  dipeptide  (MDP)  (NAc-Mur-L-ala-D- 
isogln) and the naturally occurring muramyl peptide(s), factor S, have recently 
been demonstrated.  We now  have amplified our  understanding of structural 
requirements for somnogenic activity. The effects of several analogs of MDP on 
rabbit slow-wave sleep are presented and these results are compared to the dose- 
response  relationship  for  MDP.  Some  tentative  conclusions  as  to  structural 
requirements for somnogenic activity are presented; most notably, amidation of 
the free 3,-carboxyl of MDP and several of its analogs resulted in  the loss  of 
somnogenic activity. MDP also can induce febrile and immunostimulatory re- 
sponses.  In  the  present  paper,  we  show  that  some analogs  possess  immuno- 
stimulatory and pyrogenic activity but not somnogenic activity, thus suggesting 
that these biological activities of muramyl peptides may, in part, be mediated by 
separate mechanisms. 
We thank Dr. John R. Pappenheimer for his advice and encouragement. 
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